Redundant mechanisms for vascular growth factors in retinopathy of prematurity in vitro

Ophthalmic Research

Volumn 45, Issue 2, 2011, Pages 92-101

  Xiang, Nan ^a   Zhao, Min Jian ^b   Li, Xin Yu ^a   Zheng, Hai Hong ^c   Li, Gui Gang ^a   Li, Bin ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b Central Hospital of Ezhou City   (China)

^c HUBEI UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Growth factor; Redundancy; Retinopathy of prematurity; Vascular endothelial growth factor

Indexed keywords

ANGIOPOIETIN 1; BASIC FIBROBLAST GROWTH FACTOR; BEVACIZUMAB; GROWTH FACTOR; RNA; VASCULOTROPIN;

ADENOVIRUS 2; ADULT; ARTICLE; CELL CYCLE; CONTROLLED STUDY; DRUG MECHANISM; ENDOTHELIUM CELL; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; IN VITRO STUDY; MITOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RETINA CELL; RETINA NEOVASCULARIZATION; RETROLENTAL FIBROPLASIA; RNA INTERFERENCE; WESTERN BLOTTING;

ADULT; ANGIOPOIETIN-1; BLOTTING, WESTERN; CELL CYCLE; CELLS, CULTURED; DEPENDOVIRUS; ENDOTHELIUM, VASCULAR; FIBROBLAST GROWTH FACTOR 2; GENE EXPRESSION REGULATION; HUMANS; INFANT, NEWBORN; PLASMIDS; RETINAL NEOVASCULARIZATION; RETINAL VESSELS; RETINOPATHY OF PREMATURITY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, MESSENGER; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77955611181     PISSN: 00303747     EISSN: None     Source Type: Journal    
DOI: 10.1159/000316134     Document Type: Article

References (36)

1. Bradley J, Ju M, Robinson GS: Combination therapy for the treatment of ocular neovas-cularization. Angiogenesis 2007;10:141-148.
2. Grothey A, Ellis LM: Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies. Cancer J 2008;14:170-177.
3. Shibuya M: Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis. BMB Rep 2008;41:278-286.
4. Fleck BW, McIntosh N: Pathogenesis of retinopathy of prematurity and possible preventive strategies. Early Hum Dev 2008;84:83-88.
5. Heidary G, Vanderveen D, Smith LE: Retinopathy of prematurity: current concepts in molecular pathogenesis. Semin Ophthalmol 2009;24:77-81.
6. Cao Y, Liu Q: Therapeutic targets of multiple angiogenic factors for the treatment of cancer and metastasis. Adv Cancer Res 2007;97:203-224.
7. Benest AV, Stone OA, Miller WH, Glover CP, Uney JB, Baker AH, Harper SJ, Bates DO: Arteriolar genesis and angiogenesis induced by endothelial nitric oxide synthase overexpression results in a mature vasculature. Arterioscler Thromb Vasc Biol 2008;28:1462-1468.
8. Pichiule P, Chavez JC, LaManna JC: Hypoxic regulation of angiopoietin-2 expression in endothelial cells. J Biol Chem 2004;279:12171-12180.
9. Nomi M, Miyake H, Sugita Y, Fujisawa M, Soker S: Role of growth factors and endothelial cells in therapeutic angiogenesis and tissue engineering. Curr Stem Cell Res Ther 2006;1:333-343.
10. Karamysheva AF: Mechanisms of angiogenesis. Biochemistry (Mosc) 2008;73:751-762.
11. Mantagos IS, Vanderveen DK, Smith LE: Emerging treatments for retinopathy of prematurity. Semin Ophthalmol 2009;24:82-86.
12. Kitano H: Cancer as a robust system: implications for anticancer therapy. Nat Rev Cancer 2004;4:227-235.
13. Schrattenholz A, Soskic V: What does systems biology mean for drug development? Curr Med Chem 2008;15:1520-1528.
14. Li B, Li GG, Xiang Y, Xu LJ: VEGF affects the expression of TGF-β in retinal neovascularization: a preliminary study about redundancy of growth factor (in Chinese). Int J Ophthalmol 2008;8:2391-2393.
15. Kerbel RS: Tumor angiogenesis. N Engl J Med 2008;358:2039-2049.
16. Holmes DI, Zachary I: The vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease. Genome Biol 2005;6:209.
17. Nagy JA, Dvorak AM, Dvorak HF: VEGF-A and the induction of pathological angiogenesis. Annu Rev Pathol 2007;2:251-275.
18. Clark D, Mandal K: Treatment of retinopathy of prematurity. Early Hum Dev 2008;84:95-99.
19. Li B, Tang SB, Hu J, Gao Y, Zhang G, Lin SF, Chen JH, Li BJ: Protective effects of transcription factor HESR1 on retinal vasculature. Microvasc Res 2006;72:146-152.
20. 2, and biological activities including neurite outgrowth in PC12 cells. Scientific-World Journal 2006,6:176-186.
21. Snyder RO, Xiao X, Samulski RJ: Production of recombinant adeno-associated viral vectors; in Dracopoli N (ed): Current Protocols in Human Genetics. New York, John Wiley, 1996, pp. 1-24.
22. Villegas-Becerril E, González-Fernández R, Perula-Torres L, Gallardo-Galera JM: IGF-I, VEGF and bFGF as predictive factors for the onset of retinopathy of prematurity (ROP) (in Spanish). Arch Soc Esp Oftalmol 2006;81:641-646.
23. Umeda N, Ozaki H, Hayashi H, Miyajima-Uchida H, Oshima K: Colocalization of Tie2, angiopoietin 2 and vascular endothelial growth factor in fibrovascular membrane from patients with retinopathy of prematurity. Ophthalmic Res 2003;35:217-223.
24. Drenser KA: Anti-angiogenic therapy in the management of retinopathy of prematurity. Dev Ophthalmol 2009;44:89-97.
25. Mahadevan R, Lovley DR: The degree of redundancy in metabolic genes is linked to mode of metabolism. Biophys J 2008;94:1216-1220.
26. Krakauer DC, Plotkin JB: Redundancy, antiredundancy, and the robustness of genomes. Proc Natl Acad Sci USA 2002;99:1405-1409.
27. Louis EJ: Evolutionary genetics: making the most of redundancy. Nature 2007;449:673-674.
28. Saharinen P, Eklund L, Miettinen J, Wirkkala R, Anisimov A, Winderlich M, Nottebaum A, Vestweber D, Deutsch U, Koh GY, Olsen BR, Alitalo K: Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell-cell and cell-matrix contacts. Nat Cell Biol 2008;10:527-537.
29. Wong ET, Brem S: Antiangiogenesis treatment for glioblastoma multiforme: challenges and opportunities. J Natl Compr Canc Netw 2008;6:515-522.
30. Tabernero J: The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol Cancer Res 2007;5:203-220.
31. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J: Vascular-specific growth factors and blood vessel formation. Nature 2000;407:242-248.
32. Dvorak HF: Discovery of vascular permeability factor (VPF). Exp Cell Res 2006;312:522-526.
33. Folkman J: Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007;6:273-286. (Pubitemid 46505878)
34. Mintz-Hittner HA, Kuffel RR Jr: Intravitreal injection of bevacizumab (Avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina 2008;28:831-838.
35. Mintz-Hittner HA, Best LM: Antivascular endothelial growth factor for retinopathy of prematurity. Curr Opin Pediatr 2009;21:182-187.
36. Geisen P, Peterson LJ, Martiniuk D, Uppal A, Saito Y, Hartnett ME: Neutralizing antibody to VEGF reduces intravitreous neovascularization and may not interfere with ongoing intraretinal vascularization in a rat model of retinopathy of prematurity. Mol Vis 2008;14:345-357.